Edison Investment Research - Henderson Far East Income Trust PLC (HFL) Henderson Far East Income - A strong recovery in dividend income for H122

Report

Edison Investment Research

Pedro Fonseca

Henderson Far East Income - A strong recovery in dividend income for H122

Henderson Far East Income (HFEL) focuses on providing investors with a high and growing level of income, with capital appreciation an important consideration within the investment objective. The trust has met these goals on a total return basis, with a dividend yield premium of around 50% over its Association of Investment Companies (AIC) peers. This is funded predominantly via underlying dividend income, which increased by 14.7% in H122 (31 August 2021 to 28 February 2022) versus H121.

06/05/2022 1 EN

Underlying

Henderson Far East Income Trust PLC

See profile

JE00B1GXH751 NZX Jersey

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Pedro Fonseca

Other Reports on these Companies

EQS Group AG

Edison issues update on Henderson Far East Income (HFEL): Repositioning to raise total returns

Edison Investment Research Limited Edison issues update on Henderson Far East Income (HFEL): Repositioning to raise total returns 25-Apr-2024 / 12:25 GMT/BST The issuer is solely responsible for the content of this announcement. London, UK, 25 April 2024 Edison issues update on Henderson Far East Income (HFEL): Repositioning to raise total returns Henderson Far East Income (HFEL) has consistently delivered on its objective to provide a rising dividend. However, like many investors, HFEL’s managers overestimated the potential for a post-pandemic rebound in China. The trust...

April 25, 2024 April 25, 2024 1 EN

Edison Investment Research

Henderson Far East Income - Repositioning to raise total returns

Henderson Far East Income (HFEL) has consistently delivered on its objective to provide a rising dividend. However, like many investors, HFEL’s managers overestimated the potential for a post-pandemic rebound in China. The trust’s resultant overweight to Chinese consumer and other cyclicals led to a fall in portfolio revenues and underperformance in the financial year ended 31 August 2023 (FY23). With a view to improving future returns, HFEL’s board has since indicated an increased willingness to use reserves when necessary to support dividend payments, which it did in FY23. This reduces the r...

April 25, 2024 April 25, 2024 1 EN

SmartInsider

Henderson Far East Income Ltd: 2 directors

A director at Henderson Far East Income Ltd bought 6,000 shares at 210p and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The nam...

Free Trial

January 27, 2024 January 27, 2024 1 EN

Basilea Pharmaceutica - Cresemba milestone payments continue to roll in

Basilea Pharmaceutica has announced the triggering of a US$1.25m milestone payment from Pfizer, triggered by sustained strong sales of Cresemba in the Asia-Pacific region and China. This is the second FY24 milestone payment for the region and is incremental to the payment received in March. We note that, according to the latest available data, total in-market sales of Cresemba amounted to US$473m in the 12 months ending December 2023, representing a +26% year-on-year increase. Basilea is preparing to launch its Phase III programme for fosmanogepix, a broad-spectrum antifungal therapy, with the...

13h / 54m 13h / 54m 1 EN

Toby Thorrington

Toby Thorrington

AAC Clyde Space - Solid start to the year with further order growth

AAC Clyde Space offers exposure to the fast-growing low Earth orbit space market. A solid start to the year and continued order momentum are encouraging. We also note the internal restructuring to promote delivery of the group’s products and services. We expect this combination to drive an improving performance, albeit within the lumpy nature of the business, in turn improving investor confidence and the stock’s valuation.

15h / 49m 15h / 49m 1 EN

Richard Williamson

Richard Williamson

Tinexta - Typical seasonality in Q124

Tinexta’s Q124 results showed good progress in the two divisions that typically demonstrate more consistent (through the year) growth, Cyber Security and Digital Trust, which management expects to deliver higher growth over the next few years. Business Innovation demonstrated its typical seasonality and management therefore remains confident about the outlook for the year.

17h / 15m 17h / 15m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Henderson Far East Income - A strong recovery in dividend income for H122

Edison issues update on Henderson Far East Income (HFEL): Repositioning to raise total returns

Henderson Far East Income - Repositioning to raise total returns

Henderson Far East Income Ltd: 2 directors

Basilea Pharmaceutica - Cresemba milestone payments continue to roll in

AAC Clyde Space - Solid start to the year with further order growth

Tinexta - Typical seasonality in Q124

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe